PBI-4425 / Liminal BioSci - LARVOL DELTA

[VIRTUAL] Anti-Inflammatory/Anti-Fibrotic Compound PBI-4425 Alleviates Bleomycin- and TGF-ß1-Induced Pulmonary Fibrosis (ATS-I 2020) - "In the TGF-β1 model, effects of PBI-4425 were compared with pirfenidone and nintedanib. Conclusions : PBI-4425 treatment reduced interstitial inflammation and inflammatory gene expression in bleomycin-instilled mice and attenuated AdTGF-β1-induced fibrosis in rats by preventing collagen deposition and lung function decline. These results suggest that PBI-4425 could potentially be a promising therapy for the treatment of pulmonary fibrosis."

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • IL6

[VIRTUAL] Benefits of PBI-4425 on Acute Respiratory Failure in Oleic Acid-Induced Lung Injury (ATS-I 2020) - "The animals were observed in whole-body plethysmographic chambers over 4 hours before assessment of lung compliance under Ketamine/xylazine anesthesia using a Flexivent respirator and arterial blood gas measurements. A single oral dose of PBI-4425 reduces acute respiratory failure in the oleic acid ALI model. A potential mechanism of action is by reducing neutrophil activation with reduced elastase expression correlating with down-regulation of the fatty acid receptor GPR84."

Acute Lung Injury • Acute Respiratory Distress Syndrome • Anesthesia • Respiratory Diseases • ELANE

Benefits of PBI-4425 on Acute Respiratory Failure in Oleic Acid-Induced Lung Injury (ATS 2020) - "The animals were observed in whole-body plethysmographic chambers over 4 hours before assessment of lung compliance under Ketamine/xylazine anesthesia using a Flexivent respirator and arterial blood gas measurements. A single oral dose of PBI-4425 reduces acute respiratory failure in the oleic acid ALI model. A potential mechanism of action is by reducing neutrophil activation with reduced elastase expression correlating with down-regulation of the fatty acid receptor GPR84."

Acute Lung Injury • Acute Respiratory Distress Syndrome • Anesthesia • Pulmonary Disease • Respiratory Diseases • ELANE

Anti-Inflammatory/Anti-Fibrotic Compound PBI-4425 Alleviates Bleomycin- and TGF-ß1-Induced Pulmonary Fibrosis (ATS 2020) - "In the TGF-β1 model, effects of PBI-4425 were compared with pirfenidone and nintedanib. Intratracheal instillation of bleomycin (0.065 mg/mouse) was performed on female C57BL/6 mice on day 0, treatments with PBI-4425 (200 mg/kg/day, p.o.) or vehicle started on day 7, and animals sacrificed on day 21. PBI-4425 treatment reduced interstitial inflammation and inflammatory gene expression in bleomycin-instilled mice and attenuated AdTGF-β1-induced fibrosis in rats by preventing collagen deposition and lung function decline. These results suggest that PBI-4425 could potentially be a promising therapy for the treatment of pulmonary fibrosis."

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • IL6